Literature DB >> 28270487

Missed opportunity from randomised controlled trials of medical interventions for open-angle glaucoma.

Andrew Law1, Kristina Lindsley1, Benjamin Rouse1, Richard Wormald2, Kay Dickersin1, Tianjing Li1.   

Abstract

PURPOSE: To evaluate the extent to which intraocular pressure and visual field have been reported as outcomes in randomised controlled trials (also referred to as 'trials') of medical treatments for open-angle glaucoma.
METHODS: We identified published reports of trials in a systematic review of medical interventions for open-angle glaucoma our group conducted. We assessed whether intraocular pressure and visual field were reported as trial outcomes and classified them to be either completely or incompletely reported for meta-analysis. We also collected data on the length of time patients were followed and source of funding for the trial.
RESULTS: As of March 2014, we identified 401 trials that had enrolled 76 861 participants. Eighty per cent of 401 trials provided complete information on intraocular pressure and 11% of the 401 trials provided complete information on visual field. Only a minority of trials followed patients for at least 1 year. About half of all reports in our study stated that receiving funding from the industry.
CONCLUSIONS: Although the vast majority of trials provided sufficient data for meta-analysis of the effect of medical management of open-angle glaucoma on intraocular pressure, relatively few provided data for analysing the effect on visual field. We considered this as missed opportunity because the data were not available for evidence synthesis. Investigators have an obligation to patients and providers to determine the comparative effectiveness of glaucoma interventions in terms of patient-important outcomes and not to waste data that could have been collected in trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Clinical Trial; Epidemiology; Glaucoma; Intraocular pressure; Public health

Mesh:

Substances:

Year:  2017        PMID: 28270487      PMCID: PMC5589493          DOI: 10.1136/bjophthalmol-2016-309695

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Screening for glaucomatous visual field loss with automated threshold perimetry.

Authors:  A Sommer; C Enger; K Witt
Journal:  Am J Ophthalmol       Date:  1987-05-15       Impact factor: 5.258

2.  Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.

Authors:  David F Garway-Heath; David P Crabb; Catey Bunce; Gerassimos Lascaratos; Francesca Amalfitano; Nitin Anand; Augusto Azuara-Blanco; Rupert R Bourne; David C Broadway; Ian A Cunliffe; Jeremy P Diamond; Scott G Fraser; Tuan A Ho; Keith R Martin; Andrew I McNaught; Anil Negi; Krishna Patel; Richard A Russell; Ameet Shah; Paul G Spry; Katsuyoshi Suzuki; Edward T White; Richard P Wormald; Wen Xing; Thierry G Zeyen
Journal:  Lancet       Date:  2014-12-19       Impact factor: 79.321

3.  Measuring visual field progression in the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Boel Bengtsson; Bo Bengtsson; Mohamed Hussein
Journal:  Acta Ophthalmol Scand       Date:  2003-06

Review 4.  Biomarkers and surrogate endpoints in glaucoma clinical trials.

Authors:  Felipe A Medeiros
Journal:  Br J Ophthalmol       Date:  2014-07-17       Impact factor: 4.638

Review 5.  Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.

Authors:  Tianjing Li; Kristina Lindsley; Benjamin Rouse; Hwanhee Hong; Qiyuan Shi; David S Friedman; Richard Wormald; Kay Dickersin
Journal:  Ophthalmology       Date:  2015-10-31       Impact factor: 12.079

6.  How to increase value and reduce waste when research priorities are set.

Authors:  Iain Chalmers; Michael B Bracken; Ben Djulbegovic; Silvio Garattini; Jonathan Grant; A Metin Gülmezoglu; David W Howells; John P A Ioannidis; Sandy Oliver
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321

Review 7.  Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability.

Authors:  Ian J Saldanha; Kay Dickersin; Xue Wang; Tianjing Li
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

  7 in total
  4 in total

1.  Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection: Understanding the Limitations of the Evidence.

Authors:  Laura E Downie; Richard Wormald; Jennifer Evans; Gianni Virgili; Peter R Keller; John G Lawrenson; Tianjing Li
Journal:  JAMA Ophthalmol       Date:  2019-06-01       Impact factor: 7.389

Review 2.  Cochrane Eyes and Vision: a perspective introducing Cochrane Corner in Eye.

Authors:  Jennifer Evans; Tianjing Li; Gianni Virgili; Richard Wormald
Journal:  Eye (Lond)       Date:  2019-02-19       Impact factor: 3.775

3.  Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies.

Authors:  Leonard A Levin; Mohor Sengupta; Laura J Balcer; Mark J Kupersmith; Neil R Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-11-01       Impact factor: 4.799

4.  Outcome choice and definition in systematic reviews leads to few eligible studies included in meta-analyses: a case study.

Authors:  Ian J Saldanha; Kristina B Lindsley; Sarah Money; Hannah J Kimmel; Bryant T Smith; Kay Dickersin
Journal:  BMC Med Res Methodol       Date:  2020-02-11       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.